1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Chronic Illness in 28 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the duodenal ulcerogen cysteamine on gastric emptying of a liquid meal was compared to that of two newly identified duodenal ulcerogens, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and mepirizole." | 3.67 | Biphasic effect of duodenal ulcerogens on gastric emptying in the rat. ( Kline, TJ; Pihan, G; Szabo, S, 1988) |
| "Although the initial events of sporadic Parkinson's disease (PD) are not known, consistent evidence supports the hypothesis that the disease results from the combined effect of genetic and environmental risk factors." | 1.43 | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease. ( Di Meco, A; Lauretti, E; Merali, S; Praticò, D, 2016) |
| " Here we extended the study and investigated TNF-alpha receptor 1 (-/-) (TNFR1) and TNF-alpha receptor 2 (-/-) (TNFR2) mice using a chronic MPTP dosing regimen (15 mg/kg MPTP on 8 consecutive days)." | 1.33 | Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. ( Feldon, J; Ferger, B; Leng, A; Mura, A, 2005) |
| " These data indicate that differences in striatal glutamate function appear to be associated with the dosing interval of MPTP administration and the variable loss of striatal TH immunolabeling." | 1.32 | Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. ( Freeman, P; Krentz, L; Meshul, CK; Moore, C; Robinson, S; Touchon, JC, 2003) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.71) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 7 (25.00) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 2 |
| Sun, B | 1 |
| Yang, J | 1 |
| Chen, Z | 1 |
| Li, Z | 1 |
| Zhang, N | 1 |
| Li, H | 1 |
| Shen, L | 1 |
| McQuade, RM | 1 |
| Singleton, LM | 1 |
| Wu, H | 1 |
| Lee, S | 1 |
| Constable, R | 1 |
| Di Natale, M | 1 |
| Ringuet, MT | 1 |
| Berger, JP | 1 |
| Kauhausen, J | 1 |
| Parish, CL | 1 |
| Finkelstein, DI | 1 |
| Furness, JB | 1 |
| Diwakarla, S | 1 |
| Sekar, S | 1 |
| Mani, S | 1 |
| Rajamani, B | 1 |
| Manivasagam, T | 1 |
| Thenmozhi, AJ | 1 |
| Bhat, A | 1 |
| Ray, B | 1 |
| Essa, MM | 1 |
| Guillemin, GJ | 1 |
| Chidambaram, SB | 1 |
| Yeo, S | 1 |
| Lim, S | 1 |
| Muñoz-Manchado, AB | 1 |
| Villadiego, J | 1 |
| Romo-Madero, S | 1 |
| Suárez-Luna, N | 1 |
| Bermejo-Navas, A | 1 |
| Rodríguez-Gómez, JA | 1 |
| Garrido-Gil, P | 1 |
| Labandeira-García, JL | 1 |
| Echevarría, M | 1 |
| López-Barneo, J | 1 |
| Toledo-Aral, JJ | 1 |
| Yang, B | 1 |
| Sun, H | 1 |
| Zhou, Y | 1 |
| Liu, M | 1 |
| Ding, J | 1 |
| Fang, F | 1 |
| Fan, Y | 1 |
| Hu, G | 1 |
| Lauretti, E | 1 |
| Di Meco, A | 1 |
| Merali, S | 1 |
| Praticò, D | 1 |
| Barber-Singh, J | 1 |
| Seo, BB | 1 |
| Nakamaru-Ogiso, E | 1 |
| Lau, YS | 2 |
| Matsuno-Yagi, A | 1 |
| Yagi, T | 1 |
| Xu, G | 1 |
| Xiong, Z | 1 |
| Yong, Y | 1 |
| Wang, Z | 1 |
| Ke, Z | 1 |
| Xia, Z | 1 |
| Hu, Y | 1 |
| Al-Jarrah, M | 1 |
| Jamous, M | 1 |
| Al Zailaey, K | 1 |
| Bweir, SO | 1 |
| Gross, CE | 3 |
| Ravenscroft, P | 1 |
| Dovero, S | 2 |
| Jaber, M | 1 |
| Bioulac, B | 3 |
| Bezard, E | 3 |
| Robinson, S | 1 |
| Freeman, P | 1 |
| Moore, C | 2 |
| Touchon, JC | 1 |
| Krentz, L | 1 |
| Meshul, CK | 2 |
| Miller, RM | 1 |
| Callahan, LM | 1 |
| Casaceli, C | 1 |
| Chen, L | 1 |
| Kiser, GL | 1 |
| Chui, B | 1 |
| Kaysser-Kranich, TM | 1 |
| Sendera, TJ | 1 |
| Palaniappan, C | 1 |
| Federoff, HJ | 1 |
| Dervan, AG | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Totterdell, S | 2 |
| Snyder, AK | 1 |
| Meredith, GE | 2 |
| Leng, A | 1 |
| Mura, A | 1 |
| Feldon, J | 1 |
| Ferger, B | 1 |
| Hald, A | 1 |
| Van Beek, J | 1 |
| Lotharius, J | 1 |
| Oizumi, H | 1 |
| Hayashita-Kinoh, H | 1 |
| Hayakawa, H | 1 |
| Arai, H | 1 |
| Furuya, T | 1 |
| Ren, YR | 1 |
| Yasuda, T | 1 |
| Seki, T | 1 |
| Mizuno, Y | 1 |
| Mochizuki, H | 1 |
| Wright, JM | 1 |
| Wall, RA | 1 |
| Perry, TL | 1 |
| Paty, DW | 1 |
| Rothblat, DS | 1 |
| Schneider, JS | 2 |
| Taylor, JR | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Sladek, JR | 1 |
| Redmond, DE | 1 |
| Imbert, C | 1 |
| Deloire, X | 1 |
| Zhang, Z | 1 |
| Zhang, M | 1 |
| Ai, Y | 1 |
| Avison, C | 1 |
| Gash, DM | 1 |
| Decamp, E | 1 |
| Wade, T | 1 |
| Chassain, C | 1 |
| Eschalier, A | 1 |
| Durif, F | 1 |
| Petroske, E | 1 |
| Callen, S | 1 |
| Kline, TJ | 1 |
| Pihan, G | 1 |
| Szabo, S | 1 |
| Ballard, PA | 1 |
| Tetrud, JW | 1 |
| Langston, JW | 1 |
1 review available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Chronic Illness
| Article | Year |
|---|---|
Inflammation in Parkinson's disease: causative or epiphenomenal?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disea | 2007 |
27 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Chronic Illness
| Article | Year |
|---|---|
Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Blotting, Western; Chroni | 2022 |
The association of enteric neuropathy with gut phenotypes in acute and progressive models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Cell Count; Chronic Disease; C | 2021 |
Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II Type 1 Receptor Blockers; Animals; Astr | 2018 |
Acupuncture Inhibits the Increase in Alpha-Synuclein by Modulating SGK1 in an MPTP Induced Parkinsonism Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; alpha-Synuclein; Animals; Chronic | 2019 |
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Catecholamines; Chronic D | 2016 |
Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Aquaporin 4; Astrocytes; Chron | 2016 |
Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Chronic Disease; Dis | 2016 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corp | 2010 |
Endurance exercise training promotes angiogenesis in the brain of chronic/progressive mouse model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, CD34; Blood Vessels; Chronic Diseas | 2010 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; C | 2003 |
Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Chronic Disease; Corpus Striat | 2003 |
Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Cycle; Cell Death; Chronic Disease; Cyto | 2004 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chronic Disease; Corpus Striatum; Cytoprotect | 2005 |
Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Biomarkers; Caspases; Caspases | 2008 |
Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Adult; Chronic Disease; Hu | 1984 |
Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Cell Count; Chronic Disease; Corpus Str | 1995 |
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Chron | 1997 |
Kinetics of nigral degeneration in a chronic model of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Chronic Dis | 1997 |
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Dis | 1997 |
MPTP-Induced pallidal lesions in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Chronic Disease; Female | 1999 |
Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Benzazepines; Chronic Disease; | 1999 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2001 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |
Biphasic effect of duodenal ulcerogens on gastric emptying in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chronic Disease; Cysteamine; Drug Administrat | 1988 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug | 1985 |